Lee JW, et al. - Via a systematic review and meta-analysis, researchers assessed the diagnostic performance of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET) or PET/computed tomography (PET/CT) for recurrence detection post-treatment of malignant melanoma (MM). From PubMed and EMBASE databases, relevant studies were identified. Across studies, sensitivities and specificities and positive and negative likelihood ratios (LR+ and LR–) were inquired, and summary receiver operating characteristic (SROC) curves were constructed. For ¹⁸F-FDG-PET or PET/CT, the pooled sensi­tivity across 14 results from 11 studies was 0.94 with heterogeneity (I² = 57.95) and pooled specificity was 0.91 without heterogeneity (I² = 27.24). An area under the curve of 0.96 (95% CI 0.93–0.97) was indicated by the hierarchical SROC curve. As per findings, ¹⁸F-FDG-PET or PET/CT was found to have high sensitivity and specificity for the detection of recurrent disease following treatment of MM. The utility of ¹⁸F-FDG-PET or PET/CT for exclusion and confirmation of recurrent disease following treatment of MM was indicated by the LR scattergram.